Myeloma Clinical Trials

There are hundreds of clinical trials for patients with Multiple Myeloma, Smoldering Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS) around the US. Below is a featured listing of clinical trials to help you get started. Please use the options on the side bar to find trials based on your diagnosis.


Create Your Account

Create your account today and get matched to eligible myeloma clinical trials.

  • Find clinical trials in your home town or around the country.
  • Find a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma

This is a phase 1 study of SEA-BCMA, a type of treatment called a monoclonal antibody. Antibodies are part of your immune system. Usually, they help protect you from getting sick. With SEA-BCMA, we are using an antibody designed to stick to the multiple myeloma cells in your body. The antibody sends a signal to other cells in your immune system that kill the cancer cells.

Learn more about this trial


Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

The purpose of this study is to test whether RO6870810 is safe at different dose levels, to find out what effects, good or bad, RO6870810 has on you and your disease as monotherapy or in combination with daratumumab in participants with relapsed/refractory multiple myeloma.

Learn more about this trial


Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.

No travel is required to participate in this observational trial.

Learn more about this trial


Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (PCROWD)

The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.

No travel is required to participate in this observational trial.

Learn more about this trial


Recently Updated

The INSIGHT MM Study: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma

The INSIGHT MM study is an observational study that may provide a better understanding of current multiple myeloma patients globally, and ways in which they are cared for after they are diagnosed. By participating, you are helping researchers evaluate the effectiveness of interventions for treating diseases in a real-world setting, which can give doctors a better understanding of the health outcomes of complex medical conditions.

Learn more about this trial


Recently Updated

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.

Learn more about this trial


A Phase 1/2a Study Investigating TAK-079 Administered Subcutaneously in Patients With Relapsed/Refractory Multiple Myeloma

This is a phase 1/2a study evaluating the safety, tolerability and the most appropriate dose, of TAK-079 monotherapy as treatment for patients with Relapsed/Refractory Multiple Myeloma.

Learn more about this trial


PRospective Multiple Myeloma Impact Study (PROMMIS)

We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.

Learn more about this trial


An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1)

CLOVER-1 is a multicenter, open-label, Phase 2 study evaluating intravenous (IV) administration of CLR 131 in patients with B-cell malignancies who have been previously treated with standard therapy for their underlying malignancy.

Learn more about this trial


Recently Updated

A Phase 1 Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

This is an investigational study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma. The treatment uses your own T cells to try to kill your cancerous multiple myeloma cells.

Learn more about this trial


Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

THE PROMISE study is the first study to test healthy people who may be at risk for early warning signs of a blood cancer called multiple myeloma.

No travel is required to participate in this observational trial.

Learn more about this trial


Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment.

Learn more about this trial


Study of CD8+ anti-BCMA CAR T-cells in Patients with Multiple Myeloma

This Phase 1 study will evaluate the safety and feasibility of an investigational CAR-T cell therapy called Descartes-08 in eligible patients with active multiple myeloma.

Learn more about this trial


An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

This is an investigational immuno-therapy study that is designed to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab. The study will determine the safety in subjects that receive nivolumab when given in combination with daratumumab, or dartartumumab alone in relapsed and/or refractory multiple myeloma.

Learn more about this trial


Recently Updated

A study to explore the safety and clinical activity of GSK2857916 when given with pembrolizumab in study participants with relapsed/refractory multiple myeloma (DREAMM 4)

This research study is being done to learn more about relapsed/refractory multiple myeloma, and if the study drug GSK2857916 given in combination with pembrolizumab can improve your relapsed/refractory multiple myeloma or make you feel better.

Learn more about this trial


A Study of two investigational drugs including PVX-410 (a Multi-Peptide Cancer Vaccine), and Citarinostat (a Histone Deacetylase Inhibitor (HDAC)) +/- Lenalidomide for Patients with Moderate or High Risk of Progression Smoldering Multiple Myeloma

This phase 1 research study is evaluating an immunotherapy as a possible treatment for moderate/high risk Smoldering Multiple Myeloma. The following investigational treatments will be involved in this study: PVX-410, Citarinostat (CC-96241) and Lenalidomide (Revlimid).

Learn more about this trial

;